No CrossRef data available.
Article contents
Romanow on Pharmaceuticals: A Strong Case for Access to Quality Medication Therapy
Published online by Cambridge University Press: 31 March 2010
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorials: Perspectives on the Romanow Commission Report/Éditoriaux : Perspectives sur le Rapport de la Commission Romanow
- Information
- Canadian Journal on Aging / La Revue canadienne du vieillissement , Volume 22 , Issue 1 , Spring/Printemps 2003 , pp. 25 - 28
- Copyright
- Copyright © Canadian Association on Gerontology 2003
References
Refferrencces
1Commission on the Future of Health Care in Canada. Building on values: the future of health care in Canada—final report. Ottawa: Government of Canada; 2002. p. 190.Google Scholar
2Taylor, MG. Health insurance and Canadian public policy: the seven decisions that created the Canadian health insurance system and their outcomes. 2nd ed. Montreal: McGill-Queen's University Press; 1987.Google Scholar
3Millar, WJ. Disparities in prescription drug insurance coverage. Health Rep 1999;10:11–21.Google ScholarPubMed
4Canadian Institute for Health Information. Drug expenditure in Canada, 1985–2001. Ottawa: Canadian Institute for Health Information; 2002.Google Scholar
5Willison, D, Grootendorst, P, Hurley, J. Variation in pharmacare coverage across Canada. McMaster Centre for Health Economics and Policy Analysis Research Working Paper 9808; September 1998.Google Scholar
6Menec, VH, MacWilliam, L, Sooden, RA, Mitchell, L. The health and health care use of Manitoba's seniors: have they changed over time? Winnipeg, MB: Manitoba Centre for Health Policy; 2002Google Scholar
7Soumerai, SB, Ross-Degnan, D, Avorn, J, McLaughlin, T, Choodnovskiy, I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072–7.CrossRefGoogle ScholarPubMed
8Tamblyn, R, Laprise, R, Hamley, JA, Abrahamowicz, M, Scott, S, Mayo, N, et al. . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421–9.CrossRefGoogle ScholarPubMed
9Cox, ER, Henderson, RR. Prescription use behaviour among medicare beneficiaries with capped prescription benefits. J Managed Care Pharmacy 2002;8:360–4.CrossRefGoogle ScholarPubMed
10Kozyrskyj, AL, Morgan, S, Dahl, M. Manitoba prescription cost data: an analysis for the Romanow Commission (unpublished data). Winnipeg, MB; September 2002.Google Scholar
11Willcox, SMM, Himmelstein, DU, Woolhandler, D. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292–6.CrossRefGoogle ScholarPubMed
12Tamblyn, RM, McLeod, PJ, Abrahamowicz, M, Monette, J, Gayton, DC, Berkson, L, et al. . Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150: 1801–9.Google ScholarPubMed
13Mannesse, CK, Derkx, FHM, de Ridder, MAJ, Veld, AJM, van der Cammen, TJM. Contribution of adverse drug reactions to hospital admissions of older patients. Age Ageing 2000;29:35–9.CrossRefGoogle ScholarPubMed
14Lipton, HL, Bero, LA, Bird, JA, McPhee, SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing: a randomized controlled trial. Med Care 1992;30:646–58.CrossRefGoogle ScholarPubMed
15Anderson, GF, Hussey, PS. Population aging: a comparison among industrialized countries. Health Aff 2000 May/June;19:191–203.CrossRefGoogle ScholarPubMed
16Romanow, RJ. Statement given on the release of the final report of the Commission on the Future of Health Care in Canada, National Press Theatre, Ottawa, November 28, 2002. http://www.healthcarecommission.ca/Google Scholar
You have
Access